Major depressive disorder research hub

Monitoring the AD effects of ketamine in MDD patients

This study is looking at how a medicine called ketamine affects people with severe depression. Researchers want to understand its effects better to see if it could be a helpful treatment. It’s an early-stage study, meaning they are carefully checking how the body reacts to the medicine.

A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder

This study is looking into a new medication for depression. It aims to see if different doses of this new drug, called BI 1569912, can help people with major depression feel better and if it's safe to use. Patients will take the new drug alongside their usual treatment.

Single Ascending Dose study of ENX-104

Researchers are studying a new medicine called ENX-104 for people with depression. This first study in humans will help find a safe dose and see how the body handles the medicine. It's an early step to see if ENX-104 could help treat depression in the future.

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

This study looks at a new medicine called BH-200 for adults with severe depression. It compares BH-200 to a dummy pill to see if it helps improve mood and daily life better, and if it's safe.

An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)

This study is testing a new medicine, JNJ-67953964, for adults with depression. It aims to see if it's safe and effective when added to their usual treatment over a long period. We'll monitor health, mood, and any side effects.

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study is looking into a new medication called NBI-1065845 for people with depression who haven't fully responded to their current antidepressants. It will compare the new medication to a dummy pill (placebo) to see if it helps improve symptoms when added to existing treatment.

Trial of Mirtazapine for Depression in IBD

Comorbid Obesity and Depression With an Anti-inflammatory Medication

This study looks into using a medicine called minocycline for people who have both obesity and depression. It's for those with signs of body inflammation. The aim is to see if this treatment can help improve depression symptoms by reducing inflammation.

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

This study looks into new ways to treat severe depression when first treatments haven't worked well. It compares an intensive use of esketamine (a type of ketamine) with usual care, aiming to find better and faster relief for people struggling with depression.

A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

This study is testing a new medicine, GM-2505, for moderate to severe depression. It's looking at how safe it is and if it helps people feel better. We're inviting adults aged 18-65 with depression to take part.

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study is looking at a new medicine called NBI-1065845 for people with depression. It's for those already taking antidepressants but still struggling. The main goal is to check its long-term safety and if people can take it alongside their usual treatment.

Exploring the Pharmacomicrobiomics of Depression

This study looks at how a common antidepressant called venlafaxine affects the germs in your gut and how that relates to your depression symptoms and any side effects you might have. It hopes to understand how gut changes link to treatment results.

Thiopental Induction Dose during Electroconvulsive therapy for depression (TIDE) - a randomized controlled trial of the effect of anesthetic dose during electroconvulsive therapy for major depression

This study looks at how different amounts of the medicine thiopental, used for sleep during electroconvulsive therapy (ECT), affect treatment for severe depression. Researchers want to see if a lower dose works better than a higher dose for improving mood.

A Phase III Long-Term Extension Trial with Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants with Major Depressive Disorder (EXTEND)

This study looks at a new medicine called CYB003 for people with depression. It's for those who have already shown improvement in previous studies. The main goal is to see if the medicine helps prevent depression from coming back over a long time and to check its safety.

Antidepressant effects of psilocybin in the absence of serotoninergic psychedelic experience: a dimensional functional neuroimaging approach

This study is looking into a new medication called pimavanserin for major depression. It aims to see if this drug can help improve depression by looking at brain activity, even if participants don't feel the 'psychedelic' effects typically associated with some other treatments.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropion Hydrochloride Extended Release Capsules 150 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with WELLBUTRIN XL (Bupropion hydrochloride) extended release tablets 300 mg, Distributed by: Bausch Health US, LLC Bridgewater, NJ 08807 USA. Manufactured by: Bausch Health Companies, Inc. Steinbach, MB R5G 1Z7, Canada, in healthy, adult, human subjects under fasting condition.

This study is comparing two versions of a depression medicine called bupropion. We want to see if a new generic version works the same way in your body as the well-known medicine, Wellbutrin XL. This involves healthy adults taking both medicines at different times.

An open label, balanced, randomized, three treatment, three period, three sequence, single dose, crossover study to assess the effect of food and effect of apple sauce on bioavailability of the Test product (Bupropion Hydrochloride Extended Release Capsules 150 mg, manufactured by Sun Pharmaceutical Industries Limited, India) in healthy, adult, human subjects.

This study looks at how a specific antidepressant medicine, Bupropion, is absorbed by the body when taken with or without food, or with applesauce. It's for healthy adults and helps us understand the best way to take this medicine.

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

This study is looking at a new drug called ELE-101 for depression. It checks how safe it is and how it works in healthy people first, then in people with depression, to see if it could be a helpful new treatment.